GlaxoSmithKline needs to review top management, activist investor Elliott Management says
The request comes amid debates around the competence of chief executive Emma Walmsley
Company
GSK PLC
LON:GSK
GSK PLC will be a fully focused biopharma company following the demerger of its world-leading consumer healthcare business, Haleon, in July 2022. The company will prioritise innovation in vaccines and specialty medicines, maximising the increasing opportunities to prevent and treat disease.
743 stories · page 4 of 8
GlaxoSmithKline quells market concerns for now but hard work yet to start
Chief executive Emma Walmsley presented her new strategy on Wednesday in what was seen as a 'make it or break it' event for her career
GlaxoSmithKline: Did CEO's revamp plan pass City muster? One leading bank has its say
Deutsche Bank upgraded its stock recommendation after the capital markets day
GSK on the rise after under fire chief executive unveils new five-year plan
The new strategy seemed to please investors, who are set to ask more questions on Wednesday afternoon's event
GlaxoSmithKline Investor Update: Live blog of Emma Walmsley statement
Proactive's live blog of GSK's media call with Emma Walmsley
Archive
Crunch time for GSK on Wednesday; Berkeley to report on London housing exodus
The pharma giant will kick off its eagerly anticipated investor day at the mid-point of the week
GlaxoSmithKline share price surge keeps Emma Walmsley’s head above water, but for how long?
The chief executive may be heading for an uncomfortable Capital Markets Day with activist investor Elliott leading the questioning
There’s deep value in GlaxoSmithKline, says City broker
The implied negative pipeline value is unwarranted as there are “gold star assets” with potential to fill the £3bn sales hole left by the upcoming dolutegravir patent expiry
GlaxoSmithKline snaps up promising cancer treatment ahead of crunch investor day
The announcement came ahead of the group's capital markets day next week
GlaxoSmithKline receives US emergency authorisation for COVID-19 treatment
The group has also announced the start of late-stage trials for the COVID-19 vaccine developed with Sanofi
GSK reports positive mid-trial results for second COVID-19 vaccine
The plant-based jab has been tested in combination with GSK's pandemic adjuvant
GSK and Sanofi look to catch up in vaccine race with booster doses
Approval may come a year later after their competitors, but the pair reckon there is a need for their candidate
GSK and Sanofi reveal positive trial results for COVID-19 vaccine
The pair are targeting approval by the end of the year
GlaxoSmithKline may not be doing so well compared to peers, City says
Chief executive Emma Walmsley expressed firm commitment to her plans after the spinoff on Wednesday, which may leave Elliott Management little leeway with its agenda
GlaxoSmithKline emerges as unlikely loser of COVID-19 pandemic – but will a return to normality be enough to sort out trouble?
Restrictions have hindered several of its programmes, but some issues may not resolve with the end of the pandemic
GlaxoSmithKline pins hopes on return to normality as quarterly turnover slides
The pharma giant will release more updates on the Consumer Healthcare spinoff and a new dividend policy in June
Frontier IP sees maturity spread across portfolio companies
The investment firm focuses on providing consultancy services to universities and other research organisations to help them commercialise any intellectual property arising from their research
GlaxoSmithKline to drop quarterly results as Elliot presence signals it’s time for change
JP Morgan expect revenue to slide 11% to £7.7bn after the rollout of Shingrix was hindered by the pandemic
GlaxoSmithKline receives US approval for endometrial cancer treatment
The trial showed an overall response rate of 42.3% and a duration of response of six months or more for 93.3% of participants
GlaxoSmithKline biopharma spinoff to deliver solid sales growth contrary to market scepticism, says City broker
Liberum expects a spike in revenue after short-term headwinds this and next year
GlaxoSmithKline shares rally on report activist Elliot has stake
The activist fund manager has acquired what was described as a significant stake,
GlaxoSmithKline to help produce 60mln Novavax soon-to-be approved COVID-19 vaccine doses in UK plant
Novavax is expecting a decision from the regulator as soon as next month
GlaxoSmithKline dismisses former US vaccine executive from board of investee over sexual harassment allegations
The inappropriate conduct would have happened while Moncef Slaoui was still working at the pharma giant
GlaxoSmithKline starts fast-track coronavirus vaccine trial with Medicago
Medicago's candidate, in combination with Glaxo's pandemic adjuvant, has been granted Fast Track designation by the FDA
GlaxoSmithKline recommended to stop COVID-19 treatment trials early because of high efficacy
The pharma giant is developing a monoclonal antibody with US biotech Vir
GlaxoSmithKline tweaks COVID-19 treatment study after missing primary goal
The pharma giant is expanding the study to focus on the candidate's effects on patients aged over 70
GlaxoSmithKline and Sanofi to push ahead with phase II trial of Covid-19 vaccine
“We are confident that our vaccine candidate has strong potential and we are very encouraged by the latest preclinical data"
DNA testing company 23andMe to float using Richard Branson's cash shell
Previous backers include GlaxoSmithKline, which invested US$300mln in 2018 as part of an exclusive four-year collaboration deal
GlaxoSmithKline downgraded to ‘sell’ by Deutsche Bank after results worse than expected
Analysts remain cautious on the forecast growth rebound in 2022 because of COVID-19 disruption
TEST AUTOTAGGING - FTSE 100 dips into the red; Wall Street opens on a mixed footing following US jobs data
FTSE 100 index falls 10 pointsUS stocks start mixedUS private sector adds 174k jobs in January2.47pm: Mixed start for US stocksThe Wednesday session on Wall Street was off to a mixed start on Wednesday as investors digested the latest set o
GlaxoSmithKline expects more disruption in vaccines arm this year as governments focus on COVID-19
The firm is missing out on huge revenue upside from COVID-19 vaccines as it's months behind its competitors
GlaxoSmithKline enters €150mln collaboration with CureVac for COVID-19 vaccines
The pair will work on new jabs targeting new variants of the virus
Glaxo, Vodafone updates punctuate mid-week, US earnings eyed from Spotify and Qualcomm
Wednesday is scheduled to bring heavyweight updates from both sides of the Atlantic, while the macro diary is scheduled to see new PMI data from the UK and US service sectors
GlaxoSmithKline says ViiV receives US FDA approval for long-acting HIV regimen
Cabenuva reduces the treatment dosing days from 365 days to 12 days per year
GSK will need to cut its dividend, warns Credit Suisse
Meanwhile, another broker has Glaxo as its top pick in a pharma sector that looks poised for growth
GlaxoSmithKline-owned ViiV Healthcare receives green light for long-acting HIV treatment
ViiV’s Vocabria used in combination with Janssen Pharmaceutical’s rilpivirine injection and tablets
GlaxoSmithKline: Back to the drawing board for UK drugs giant and French partner in their bid to deliver coronavirus vaccine
It is the first setback in a largely successful quest for a vaccine
GlaxoSmithKline down to neutral as UBS awaits more details on separation of consumer health arm
The bank said while the pharma firm saw the separation as an “opportunity to reset its debt” there were also questions about what would happen to its dividend
GlaxoSmithKline says HIV prevention candidate more effective than standard of care
The results came from the first study of long-acting injectable therapy for HIV prevention among women
GlaxoSmithKline upgraded to ‘hold’ by ShoreCap after recent momentum but analysts remain cautious
The broker sees structural risks from mergers and acquisitions and dividend uncertainty before the consumer spin out in 2022
GlaxoSmithKline sets net-zero environmental goals by 2030
The pharma company noted the increasing scientific evidence shows that climate issues affect human health
GlaxoSmithKline upgraded to ‘buy’ by Liberum ahead of prolonged period of earnings growth
Analysts said the pharma company is undervalued in its prospects for growth
GlaxoSmithKline holds forecast as US vaccine rates pick up
Revenues overall fell by 8% to £8.65bn, while operating profits dropped 13% to £1.87bn.
GlaxoSmithKline and Sanofi to donate 200mln doses of COVID-19 vaccine to COVAX
The two companies have signed a Statement of Intent with Gavi, the legal administrator of the COVAX Facility
Archive
GlaxoSmithKline and Next updates lead Wednesday’s corporate calendar
The pharmaceutical giant will likely be eyed for any news on vaccination rates to help drive earnings, while retailer Next will be watched as a possible bellwether for the health of the wider UK retail sector
The week in coronavirus: GlaxoSmithKline starts trials on treatment and vaccine; Zoom posts massive revenue growth; Virgin Atlantic gets rescue deal approved but cuts more jobs…
A look at the week's major news regarding the pandemic
GlaxoSmithKline, Sanofi start early-stage trial for coronavirus vaccine
The final trial is planned to start in December if data from the current one can support it
GlaxoSmithKline receives green light for bone marrow cancer drug
BLENREP is the fifth major medicine approval for GSK and the second from its oncology portfolio
GlaxoSmithKline and Sanofi to supply EU with 300mln COVID-19 vaccine doses
A Phase 1/ 2 study is expected to start in September, followed by a Phase 3 study by the end of 2020
Coronavirus: Westminster postpones Saturday’s reopenings, enforces new restrictions for 4mln people in England; US allocates US$2.1bn for GlaxoSmithKline, Sanofi vaccine
A round-up of Friday's major news regarding the pandemic
GlaxoSmithKline, Sanofi to receive up to US$2.1bn from Washington to develop coronavirus vaccine
Over US$1bn are needed to support the jab’s development such as the trials on humans
GlaxoSmithKline keeps guidance but wary over vaccination recovery
There was a sharp drop off in the second quarter as disruption from COVID-19 began to be felt
GlaxoSmithKline and Sanofi land £500mln vaccine deal as UK government continues to hedge its coronavirus bets
Britain is to buy 60mln doses of the inoculation, which has yet to enter the clinic
GlaxoSmithKline takes stake in German vaccine group targeted by Donald Trump
President Trump was reported to have offered to pay for exclusive access to CureVac's COVID-19 vaccine
GlaxoSmithKline says US advisory committee recommends blood cancer antibody approval
Analysts at Liberum see peak sales of £3.8bn if the drug is approved
GlaxoSmithKline vows to produce 1bn vaccine adjuvant to support coronavirus candidates
The pharma giant is identifying potential vaccines that could be suitable to use the agent
GlaxoSmithKline posts positive interim study on HIV prevention drug
Injectable cabotegravir is 69% more effective than daily tablets of emtricitabine/tenofovir disoproxil fumarate, the current standard of care
GlaxoSmithKline to offload entire holding in Hindustan Unilever
The pharma giant acquired the stake in December 2018 as part of a transaction with Unilever
GlaxoSmithKline receives US approval for late-stage ovarian cancer treatment
Until now, only 20% of women with ovarian cancer were eligible to be treated with a drug of the same kind
GSK profits surge on demand for coronavirus treatments and shingles drug
"Responding to the Covid-19 pandemic is at the heart of our purpose as a company," said chief executive Emma Walmsley
GlaxoSmithKline, Sanofi team up to develop coronavirus vaccine
The candidate would enter clinical trials in the second half of 2020 and be available by the end of 2021
GlaxoSmithKline injects US$250mln into US biotech Vir in coronavirus treatment collaboration
Vir's has two candidates that have proved highly potent in neutralising SARS-CoV-2 in live virus-cellular assays
GlaxoSmithKline injects cash into drug pipeline as earnings come in short
Full-year results showed turnover up 10% to £33.8bn and adjusted earnings per share up 4% to 123.9p, following a disappointing fourth quarter
FTSE 100 makes further gains as global rally continues
Britain's blue chips closed up over 42 points at 7,482. The midcap FTSE 250 added around 94 at 21,534
Health on the agenda, although coronavirus is not something Glaxo's results are likely to address
Aside from Glaxo, first-half results will be eyed from housebuilders Barratt Developments and Redrow, with Vodafone to issue an update
FTSE 100 starts February by closing higher, boosted by sterling, as no-deal fears resurface
FTSE 100 closed Monday ahead by around 40 points, or 0.55% at 7,326. Mid-cap cousin FTSE 250 gained over 63 at 21,207
GSK under the microscope in week ahead; BP and Royal Mail also eyed
Three housebuilders are also due to report on their numbers in the coming week: Barratt Developments, Bellway and Redrow
GlaxoSmithKline target price upped by UBS due to HIV drug
The ‘buy’ recommendation was maintained while the target price was lifted to 1,950p from 1,900p
GlaxoSmithKline receives HIV treatment knock-back in the USA
Glaxo's specialist HIV drugs division, in which Pfizer and Shionogi have stakes, has been developing the once-a-month injection as an alternative to daily treatments
UBS upgrades GSK as HIV business is set to grow rapidly
An injectable drug that launches in the US this year also might generate revenues of almost £700mln by 2023.
GlaxoSmithKline shares close to 17-year highs as it upgrades full-year earnings forecasts
The drugmaker now expects adjusted EPS for 2019 to be “around flat” year-on-year, an upgrade from a decline of between 3% and 5%
Archive
FTSE 100 closes higher ahead of US Fed decision; drugs titans shine
The UK's premier share index finished ahead by 24.52 points at 7,330, having been lower earlier
GSK sells two vaccines for up to €1bn
The company said it decided to sell these brands to focus on other segments within its fast-growing vaccines business
GSK recalls heartburn drug over carcinogen risk
The UK Medicines and Healthcare products Regulatory Agency (MHRA) said that all unexpired stock was going to be removed from pharmacies
GlaxoSmithKline to file blood cancer drug with regulators later this year
GSK bosses will use the results from this latest DREAMM-2 trial as the basis for the regulatory filings
GlaxoSmithKline develops HIV treatment that only needs to be taken six times a year
Glaxo already knew that its once-monthly jab worked, and it has now shown in clinical trials that the same injection but taken every two months is just as effective
Archive
Proactive news snapshot: hVIVO, Statpro, Keywords Studios...
A glance at some of the day's highlights from the Proactive Investors newswire
Midatech appoints former GSK director to the board
Midatech said it is "very confident" Frédéric Duchesne will make an "important and positive impact" to the business
Investments and investor services
FTSE 100 closes in the red as traders await first US rate cut since recession
Investors are expecting a cut of 0.25% in the benchmark short-term rate
GlaxoSmithKline lifts full-year guidance as profits double in second quarter
GSK was forced to cut its forecasts earlier this ear after a generic rival to Advair came to market, but an “improved operational performance” in the second quarter means things won’t be as bad as first feared
GSK names former AstraZeneca finance boss as new chairman
Jonathan Symonds will be the man tasked with overseeing the mega merger of GSK and Pfizer’s consumer healthcare businesses
Investments and investor services
FTSE 100 closes in red as mining stocks weigh
FTSE 100 closed in the red on Wednesday as miners weighed after a sell-off in iron ore in China
Archive
ITV investors watching for Love Island effect as new boy enters villa
The Conservative Party leadership contest was decided by a relatively convincing margin of 92,153 votes to 46,656, while Love Island commands consolidated viewing figures of more than 5mln
Investments and investor services
FTSE 100 regains positive footing at close as Wall Street makes gains
In New York, the Dow Jones Industrials Average hit 27,153 by midday, while the S&P gained 0.2% and the Nasdaq was up 0.6%.
Archive
ITV investors hope for Love Island boost amid tough ad market
The week ahead includes updates from ITV, Unilever, Rightmove, Diageo, Marston's, IG Group, National Express, GSK and AstraZeneca
GlaxoSmithKline edges higher as Zejula passes late-stage ovarian cancer study with flying colours
Zejula demonstrated a “statistically significant” improvement in progression free survival – the length of time a patient lives with the disease but it doesn’t get worse
Verona Pharma: The AIM-quoted drug developer built on the research of a Glaxo legend
Sir David Jack's team were responsible for the discovery of several huge drugs, and RPL554, a compound he helped develop later on in his career, is now being taken through the clinic by Verona
GSK’s Dovato single-pill HIV treatment sails through year-long phase III trial
GSK wanted to show that Dovato was just as effective in suppressing HIV as the current cocktail of drugs given to HIV sufferers
Archive
Barratt Developments and Bovis Homes to provide main building bricks in coming week
Aside from the two housebuilders, corporate updates in the coming week will also be delivered by retailers Ocado, Superdry and Dunelm
Morgan Stanley doesn’t think there’s much money to be made by investing in GSK
GSK is in the middle of some big changes: it is bedding in a multi-billion-dollar acquisition; rebuilding its drugs pipeline; and merging its consumer healthcare division with one of its rivals
GlaxoSmithKline gets US green light for severe asthma home treatment
The Food & Drug Administration gave approval for GSK’s Nucala to be given using an auto-injector or a pre-filled safety syringe
Immuno-oncology: All you wanted to know but were too afraid to ask
Essentially, immuno-oncology involves developing drugs that use the body’s own immune system to fight cancers
Investments and investor services
FTSE 100 closes firmly higher as Wall Street shares head north; sterling slides
The UK benchmark index closed over 56 points higher, at 7,353, aided by the fall in the pound
Archive
Burberry and Thomas Cook in the spotlight; ex-divs to take 26 points off the FTSE 100
Numbers from Countryside Properties, National Grid, and Wincanton will also be among Thursday's highlights.
Archive
Burberry, Kingfisher, Thomas Cook and Aston Martin in focus in week ahead
The week ahead's highlights include updates from Burberry, Land Securities, British Land, Premier Foods, Experian, Kingfisher, Aston Martin, Dignity, Centrica, Thomas Cook, On the Beach and Countryside Properties.
Pharma stocks head south as Trump forces them to display drug prices in TV ads
“Drug companies have to come clean about their prices in TV ads. If drug companies are ashamed of those prices – lower them!”
Vectura surges as it wins US$90mln patent battle with GlaxoSmithKline
GSK has been ordered to pay US$89.7mln after its Ellipta inhalers were found to have breached Vectura’s patents
GSK reports 30% jump in first-quarter profits as demand for its vaccines booms
Revenue edged 6% higher in the quarter to £7.66bn, with almost all of that growth coming from the vaccines business
Archive
Will Next spring a surprise in Wednesday’s first-quarter trading update?
There’s a lot for investors to get their teeth into on Wednesday, with Sainsbury’s, GSK and Persimmon among the slew of companies reporting alongside Next
Why the FTSE 100 is not the UK’s economic bellwether
While the index does contain the heavyweights of the London market, they're not the most reliable indicator of how the UK's markets are actually performing